Clinical Utility of Weekly Laboratory Testing in the Outpatient Management of Preeclampsia and Gestational Hypertension

Abstract

Objective To investigate the utility of obtaining weekly laboratory testing in patients managed as an outpatient for gestational hypertension and preeclampsia without severe features.

Study Design A multisite retrospective cohort study was performed evaluating preterm women diagnosed with gestational hypertension/preeclampsia managed in an outpatient setting between gestational ages of 23^0/7 and 36^6/7. Patients were divided into two groups: weekly laboratory evaluation (laboratories group) and a no laboratories group. The primary study outcome was composite maternal morbidity including more than one of the following: development of severe features, HELLP syndrome, eclampsia, placental abruption, maternal intensive care unit admission, or maternal death.

Results A total of 204 patients were included in this study, laboratories group (n = 120) and no laboratories group (n = 84). The laboratories group was older (28.8 vs. 26.6 years, p = 0.02), had a higher rate of chronic hypertension (44 [36.7%] vs. 17 [20.2%], p = 0.01), and more often experienced the primary composite outcome (53 [44.2%] vs. 24 [28.5%], p = 0.02). No patients in our cohort were delivered for abnormal laboratory values.

Conclusion This study found that weekly laboratory testing may have minimal clinical utility in the outpatient management protocol in monitoring patients with mild gestational hypertension or preeclampsia. Delivery was guided by other clinical factors.

Keywords

mild preeclampsia - preeclampsia without severe features - gestational hypertension - chronic hypertension in pregnancy - superimposed preeclampsia - liver enzymes - platelet count - preeclampsia with severe features

Disclosure

All authors report no conflicts of interest and have no financial disclosures to report.

Note

Oral presentation at the 86th Annual Meeting of the Central Association of Obstetricians and Gynecologists, October 19, 2019.

• References

• 1 ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia. Obstet Gynecol 2019; 133 (01) e1-e25
• 2 Barton JR, Istwan NB, Rhea D, Collins A, Stanziano GJ. Cost-savings analysis of an outpatient management program for women with pregnancy-related hypertensive conditions. Dis Manag 2006; 9 (04) 236-241
• 3 Schoen CN, Moreno SC, Saccone G. , et al. Outpatient versus inpatient management for superimposed preeclampsia without severe features: a retrospective, multicenter study. J Matern Fetal Neonatal Med 2018; 31 (15) 1993-1999
• 4 Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003; 102 (01) 181-192
• 5 ACOG Practice Bulletin No. 203: chronic hypertension in pregnancy. Obstet Gynecol 2019; 133 (01) e26-e50
• 6 Wright D, Nicolaides KH. Aspirin delays the development of preeclampsia. Am J Obstet Gynecol 2019; 220 (06) 580.e1-580.e6
• 7 Becker DA, Machemehl HC, Biggio JR, Siegel AM, Tita AT, Harper LM. Pregnancy outcomes of exacerbated chronic hypertension compared with superimposed preeclampsia. Am J Perinatol 2019; 36 (08) 872-878
• 8 Sperling JD, Dahlke JD, Huber WJ, Sibai BM. The role of headache in the classification and management of hypertensive disorders in pregnancy. Obstet Gynecol 2015; 126 (02) 297-302
• 9 Valent AM, DeFranco EA, Allison A. , et al. Expectant management of mild preeclampsia versus superimposed preeclampsia up to 37 weeks. Am J Obstet Gynecol 2015; 212 (04) 515.e1-515.e8